Person-time | Failures† | Incidence rate* | 95% CI | ||
COVID-19 infection | IBD medication category | ||||
Mesalazine | 133 994 | 247 | 18.43 | 16.27 to 20.88 | |
Thiopurine | 24 386 | 49 | 20.09 | 15.19 to 26.59 | |
Anti-TNF | 41 842 | 95 | 22.70 | 18.57 to 27.76 | |
Anti-TNF+TP | 12 549 | 33 | 26.30 | 18.69 to 36.99 | |
Anti-TNF+MTX | 5389 | 10 | 18.56 | 9.98 to 34.49 | |
Vedolizumab | 8978 | 31 | 34.53 | 24.28 to 49.10 | |
Ustekinumab | 1760 | 4 | 22.73 | 8.53 to 60.57 | |
Tofacitinib | 793 | 2 | 25.22 | 6.31 to 100.83 | |
No IBD Meds | 93 712 | 184 | 19.63 | 16.99 to 22.69 | |
Corticosteroid use | |||||
No | 301 973 | 588 | 19.47 | 17.96 to 21.11 | |
Yes | 18 876 | 61 | 32.32 | 25.14 to 41.53 | |
COVID-19 hospitalisation | IBD medication category | ||||
Mesalazine | 134 015 | 40 | 2.98 | 2.19 to 4.07 | |
Thiopurine | 24 390 | 10 | 4.10 | 2.21 to 7.62 | |
Anti-TNF | 41 859 | 13 | 3.11 | 1.80 to 5.35 | |
Anti-TNF+TP | 12 549 | 7 | 5.58 | 2.66 to 11.70 | |
Anti-TNF+MTX | 5390 | 4 | 7.42 | 2.79 to 19.77 | |
Vedolizumab | 8986 | 6 | 6.68 | 3.00 to 14.86 | |
Ustekinumab | 1759 | 1 | 5.68 | 0.80 to 40.35 | |
Tofacitinib | 793 | 0 | 0 | – | |
No IBD Meds | 93 740 | 45 | 4.80 | 3.58 to 6.43 | |
Corticosteroid use | |||||
No | 302 046 | 108 | 3.58 | 2.96 to 4.32 | |
Yes | 18 883 | 17 | 9.00 | 5.60 to 14.48 | |
COVID-19 mortality | IBD medication category | ||||
Mesalazine | 4 078 807 | 23 | 0.06 | 0.04 to 0.08 | |
Thiopurine | 742 291 | 2 | 0.03 | 0.01 to 0.11 | |
Anti-TNF | 1 273 565 | 0 | 0.00 | – | |
Anti-TNF+TP | 381 979 | 1 | 0.03 | 0.00 to 0.19 | |
Anti-TNF+MTX | 164 039 | 0 | 0.00 | – | |
Vedolizumab | 273 291 | 1 | 0.04 | 0.01 to 0.26 | |
Ustekinumab | 53 560 | 0 | 0.00 | – | |
Tofacitinib | 24 139 | 0 | 0.00 | – | |
No IBD Meds | 2 852 623 | 14 | 0.05 | 0.03 to 0.08 | |
Corticosteroid use | |||||
No | 9 253 594 | 40 | 0.04 | 0.03 to 0.06 | |
Yes | 590 700 | 1 | 0.02 | 0.00 to 0.12 |
*Reported per 10 000 person-months.
† ‘Failures’ refers to infections in the first portion of the table, hospitalisations in the second portion of the table, and mortality in the third portion of the table.
IBD, inflammatory bowel disease; MTX, methotrexate; TNF, tumour necrosis factor; TP, thiopurine.